Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin

Authors: Peter Bronsert, Ilona Kohler, Martin Werner, Frank Makowiec, Simon Kuesters, Jens Hoeppner, Ulrich Theodor Hopt, Tobias Keck, Dirk Bausch, Ulrich Friedrich Wellner

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Periampullary adenocarcinomas comprise pancreatic, distal bile duct, ampullary and duodenal adenocarcinoma. The epithelia of these anatomical structures share a common embryologic origin from the foregut. With steadily increasing numbers of pancreatoduodenectomies over the last decades, pathologists, surgeons and oncologists are more often confronted with the diagnosis of “other than pancreatic” periampullary cancers. The intestinal subtype of ampullary cancer has been shown to correlate with better prognosis.

Methods

Histological subtype and immunohistochemical staining pattern for CK7, CK20 and CDX2 were assessed for n = 198 cases of pancreatic ductal, distal bile duct, ampullary and duodenal adenocarcinoma with clinical follow-up. Routine pathological parameters were included in survival analysis performed with SPSS 20.

Results

In univariate analysis, intestinal subtype was associated with better survival in ampullary, pancreatic ductal and duodenal adenocarcinoma. The intestinal type of pancreatic ductal adenocarcinoma was not associated with intraductal papillary mucinous neoplasm and could not be reliably diagnosed by immunohistochemical staining pattern alone. Intestinal differentiation and lymph node ratio, but not tumor location were independent predictors of survival when all significant predictor variables from univariate analysis (grade, TNM stage, presence of precursor lesions, surgical margin status, perineural, vascular and lymphatic vessel invasion, CK7 and CDX2 staining pattern) were included in a Cox proportional hazards model.

Conclusions

Intestinal type differentiation and lymph node ratio but not tumor location are independent prognostic factors in pooled analysis of periampullary adenocarcinomas. We conclude that differentiation is more important than tumor location for prognostic stratification in periampullary adenocarcinomas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO classification of tumors of the digestive system. 2010, Lyon: International Agency for Research in Cancer, 4 Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO classification of tumors of the digestive system. 2010, Lyon: International Agency for Research in Cancer, 4
2.
go back to reference Adsay V, Ohike N, Tajiri T, Kim GE, Krasinskas A, Balci S, Bagci P, Basturk O, Bandyopadhyay S, Jang K-T, Kooby DA, Maithel SK, Sarmiento J, Staley CA, Gonzalez RS, Kong SY, Goodman M: Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. 2012, Pathol: Am J Surg Adsay V, Ohike N, Tajiri T, Kim GE, Krasinskas A, Balci S, Bagci P, Basturk O, Bandyopadhyay S, Jang K-T, Kooby DA, Maithel SK, Sarmiento J, Staley CA, Gonzalez RS, Kong SY, Goodman M: Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. 2012, Pathol: Am J Surg
3.
go back to reference Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, Clausen OPF, Gladhaug IP: Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008, 8: 170-10.1186/1471-2407-8-170.CrossRefPubMedPubMedCentral Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, Clausen OPF, Gladhaug IP: Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008, 8: 170-10.1186/1471-2407-8-170.CrossRefPubMedPubMedCentral
4.
go back to reference Pomianowska E, Grzyb K, Westgaard A, Clausen OPF, Gladhaug IP: Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer. Eur J Surg Oncol. 2012, 38: 1043-10.1016/j.ejso.2012.07.113.CrossRefPubMed Pomianowska E, Grzyb K, Westgaard A, Clausen OPF, Gladhaug IP: Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer. Eur J Surg Oncol. 2012, 38: 1043-10.1016/j.ejso.2012.07.113.CrossRefPubMed
5.
go back to reference Ohike N, Kim GE, Tajiri T, Krasinskas A, Basturk O, Coban I, Bandyopadhyay S, Morohoshi T, Goodman M, Kooby DA, Sarmiento JM, Adsay NV: Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases. Am J Surg Pathol. 2010, 34: 1731-1748. 10.1097/PAS.0b013e3181f8ff05.CrossRefPubMedPubMedCentral Ohike N, Kim GE, Tajiri T, Krasinskas A, Basturk O, Coban I, Bandyopadhyay S, Morohoshi T, Goodman M, Kooby DA, Sarmiento JM, Adsay NV: Intra-ampullary papillary-tubular neoplasm (IAPN): characterization of tumoral intraepithelial neoplasia occurring within the ampulla: a clinicopathologic analysis of 82 cases. Am J Surg Pathol. 2010, 34: 1731-1748. 10.1097/PAS.0b013e3181f8ff05.CrossRefPubMedPubMedCentral
6.
go back to reference Kimura W, Futakawa N, Zhao B: Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg. 2004, 11: 223-231.CrossRefPubMed Kimura W, Futakawa N, Zhao B: Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg. 2004, 11: 223-231.CrossRefPubMed
7.
go back to reference Morini S, Perrone G, Borzomati D, Vincenzi B, Rabitti C, Righi D, Castri F, Manazza AD, Santini D, Tonini G, Coppola R, Onetti Muda A: Carcinoma of the Ampulla of Vater: Morphological and Immunophenotypical Classification Predicts Overall Survival. Pancreas. 2012, 42: 60-66.CrossRef Morini S, Perrone G, Borzomati D, Vincenzi B, Rabitti C, Righi D, Castri F, Manazza AD, Santini D, Tonini G, Coppola R, Onetti Muda A: Carcinoma of the Ampulla of Vater: Morphological and Immunophenotypical Classification Predicts Overall Survival. Pancreas. 2012, 42: 60-66.CrossRef
8.
go back to reference Albores-Saavedra J, Henson DE, Klimstra DS: Tumors of the gallbladder, extrahempatic bile duct and ampulla of Vater. Atlas of Tumor Pathology. 2000, Washington DC: Armed Forces Institute of Pathology, Fascile 27 Albores-Saavedra J, Henson DE, Klimstra DS: Tumors of the gallbladder, extrahempatic bile duct and ampulla of Vater. Atlas of Tumor Pathology. 2000, Washington DC: Armed Forces Institute of Pathology, Fascile 27
9.
go back to reference Westgaard A, Pomianowska E, Clausen OPF, Gladhaug IP: Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?. Ann Surg Oncol. 2013, 20: 430-439. 10.1245/s10434-012-2603-0.CrossRefPubMed Westgaard A, Pomianowska E, Clausen OPF, Gladhaug IP: Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?. Ann Surg Oncol. 2013, 20: 430-439. 10.1245/s10434-012-2603-0.CrossRefPubMed
10.
go back to reference Pomianowska E, Westgaard A, Mathisen O, Clausen OPF, Gladhaug IP: Prognostic relevance of number and ratio of metastatic lymph nodes in resected pancreatic, ampullary, and distal bile duct carcinomas. 2012, Oncol: Ann. Surg Pomianowska E, Westgaard A, Mathisen O, Clausen OPF, Gladhaug IP: Prognostic relevance of number and ratio of metastatic lymph nodes in resected pancreatic, ampullary, and distal bile duct carcinomas. 2012, Oncol: Ann. Surg
11.
go back to reference Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F: The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009, 13: 1337-44. 10.1007/s11605-009-0919-2.CrossRefPubMed Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F: The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009, 13: 1337-44. 10.1007/s11605-009-0919-2.CrossRefPubMed
12.
go back to reference Albores-Saavedra J, Simpson K, Dancer Y-J, Hruban R: Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol. 2007, 11: 3-9. 10.1016/j.anndiagpath.2006.06.008.CrossRefPubMed Albores-Saavedra J, Simpson K, Dancer Y-J, Hruban R: Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol. 2007, 11: 3-9. 10.1016/j.anndiagpath.2006.06.008.CrossRefPubMed
13.
go back to reference Adsay NV, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC, Brennan MF, Klimstra DS: Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol. 2001, 25: 26-42. 10.1097/00000478-200101000-00003.CrossRefPubMed Adsay NV, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC, Brennan MF, Klimstra DS: Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol. 2001, 25: 26-42. 10.1097/00000478-200101000-00003.CrossRefPubMed
14.
go back to reference Adsay NV, Merati K, Basturk O, Iacobuzio-Donahue C, Levi E, Cheng JD, Sarkar FH, Hruban RH, Klimstra DS: Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004, 28: 839-848. 10.1097/00000478-200407000-00001.CrossRefPubMed Adsay NV, Merati K, Basturk O, Iacobuzio-Donahue C, Levi E, Cheng JD, Sarkar FH, Hruban RH, Klimstra DS: Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004, 28: 839-848. 10.1097/00000478-200407000-00001.CrossRefPubMed
15.
go back to reference Yopp AC, Katabi N, Janakos M, Klimstra DS, D’Angelica MI, DeMatteo RP, Fong Y, Brennan MF, Jarnagin WR, Allen PJ: Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011, 253: 968-974. 10.1097/SLA.0b013e318214bcb4.CrossRefPubMed Yopp AC, Katabi N, Janakos M, Klimstra DS, D’Angelica MI, DeMatteo RP, Fong Y, Brennan MF, Jarnagin WR, Allen PJ: Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011, 253: 968-974. 10.1097/SLA.0b013e318214bcb4.CrossRefPubMed
16.
go back to reference Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, Chen J-H, Yiannoutsos CT, Lillemoe KD, Farnell MB, Sarr MG, Schmidt CM: Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg. 2011, 213: 275-283. 10.1016/j.jamcollsurg.2011.04.003.CrossRefPubMed Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, Chen J-H, Yiannoutsos CT, Lillemoe KD, Farnell MB, Sarr MG, Schmidt CM: Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg. 2011, 213: 275-283. 10.1016/j.jamcollsurg.2011.04.003.CrossRefPubMed
17.
go back to reference Zen Y, Quaglia A, Heaton N, Rela M, Portmann B: Two distinct pathways of carcinogenesis in primary sclerosing cholangitis. Histopathology. 2011, 59: 1100-1110. 10.1111/j.1365-2559.2011.04048.x.CrossRefPubMed Zen Y, Quaglia A, Heaton N, Rela M, Portmann B: Two distinct pathways of carcinogenesis in primary sclerosing cholangitis. Histopathology. 2011, 59: 1100-1110. 10.1111/j.1365-2559.2011.04048.x.CrossRefPubMed
18.
go back to reference Rocha FG, Lee H, Katabi N, Dematteo RP, Fong Y, D’Angelica MI, Allen PJ, Klimstra DS, Jarnagin WR: Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?. Hepatology. 2012, 56: 1352-1360. 10.1002/hep.25786.CrossRefPubMed Rocha FG, Lee H, Katabi N, Dematteo RP, Fong Y, D’Angelica MI, Allen PJ, Klimstra DS, Jarnagin WR: Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?. Hepatology. 2012, 56: 1352-1360. 10.1002/hep.25786.CrossRefPubMed
19.
go back to reference Kohler I, Jacob D, Budzies J, Lehmann A, Weichert W, Schulz S, Neuhaus P, Röcken C: Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 2011, 135: 202-211. 10.1309/AJCPCTCUQSYI89YT.CrossRefPubMed Kohler I, Jacob D, Budzies J, Lehmann A, Weichert W, Schulz S, Neuhaus P, Röcken C: Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 2011, 135: 202-211. 10.1309/AJCPCTCUQSYI89YT.CrossRefPubMed
20.
go back to reference Fischer H-P, Zhou H: Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg. 2004, 11: 301-309. 10.1007/s00534-004-0898-3.CrossRefPubMed Fischer H-P, Zhou H: Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg. 2004, 11: 301-309. 10.1007/s00534-004-0898-3.CrossRefPubMed
21.
go back to reference Fischer H-P, Zhou H: Pathogenesis and histomorphology of ampullary carcinomas and their precursor lesions. Review and individual findings. Pathologe. 2003, 24: 196-203.PubMed Fischer H-P, Zhou H: Pathogenesis and histomorphology of ampullary carcinomas and their precursor lesions. Review and individual findings. Pathologe. 2003, 24: 196-203.PubMed
22.
go back to reference Gassler N, Knüchel R: Tumors of Vater’s ampulla. Pathologe. 2012, 33: 17-23. 10.1007/s00292-011-1546-8.CrossRefPubMed Gassler N, Knüchel R: Tumors of Vater’s ampulla. Pathologe. 2012, 33: 17-23. 10.1007/s00292-011-1546-8.CrossRefPubMed
23.
go back to reference Verbeke CS, Gladhaug IP: Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012, 99: 1036-1049. 10.1002/bjs.8734.CrossRefPubMed Verbeke CS, Gladhaug IP: Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012, 99: 1036-1049. 10.1002/bjs.8734.CrossRefPubMed
24.
go back to reference Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW: Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008, 15: 1651-60. 10.1245/s10434-008-9839-8.CrossRefPubMed Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Buchler MW: Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008, 15: 1651-60. 10.1245/s10434-008-9839-8.CrossRefPubMed
25.
go back to reference Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS: Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009, 11: 18-24. 10.1111/j.1477-2574.2008.00013.x.CrossRef Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS: Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009, 11: 18-24. 10.1111/j.1477-2574.2008.00013.x.CrossRef
26.
go back to reference De Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, Eckhauser F, Herman JM, Edil BH, Choti MA, Schulick RD, Pawlik TM: Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010, 102: 256-263. 10.1002/jso.21610.CrossRefPubMed De Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, Eckhauser F, Herman JM, Edil BH, Choti MA, Schulick RD, Pawlik TM: Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010, 102: 256-263. 10.1002/jso.21610.CrossRefPubMed
27.
go back to reference Michalski CW, Erkan M, Hüser N, Müller MW, Hartel M, Friess H, Kleeff J: Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg. 2008, 25: 473-480. 10.1159/000184739.CrossRefPubMed Michalski CW, Erkan M, Hüser N, Müller MW, Hartel M, Friess H, Kleeff J: Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg. 2008, 25: 473-480. 10.1159/000184739.CrossRefPubMed
28.
go back to reference Kang SP, Saif MW: Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the “2011 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 20–22, 2011. JOP. 2011, 12: 123-125.PubMed Kang SP, Saif MW: Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the “2011 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 20–22, 2011. JOP. 2011, 12: 123-125.PubMed
29.
go back to reference Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012, 308: 147-156. 10.1001/jama.2012.7352.CrossRefPubMed Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012, 308: 147-156. 10.1001/jama.2012.7352.CrossRefPubMed
30.
go back to reference Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG, Donohue JH, Schulick RD, Wolfgang CL, Cameron JL, Herman JM: Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011, 6: 126-10.1186/1748-717X-6-126.CrossRefPubMedPubMedCentral Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG, Donohue JH, Schulick RD, Wolfgang CL, Cameron JL, Herman JM: Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011, 6: 126-10.1186/1748-717X-6-126.CrossRefPubMedPubMedCentral
31.
go back to reference Palta M, Patel P, Broadwater G, Willett C, Pepek J, Tyler D, Zafar SY, Uronis H, Hurwitz H, White R, Czito B: Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol. 2012, 19: 1535-1540. 10.1245/s10434-011-2117-1.CrossRefPubMed Palta M, Patel P, Broadwater G, Willett C, Pepek J, Tyler D, Zafar SY, Uronis H, Hurwitz H, White R, Czito B: Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol. 2012, 19: 1535-1540. 10.1245/s10434-011-2117-1.CrossRefPubMed
32.
go back to reference Neoptolemos J, European Study Group for Pancreatic Cancer: Ampullary cancer ESPAC-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. J Clin Oncol. 2011, 29 (Suppl): LBA4006 Neoptolemos J, European Study Group for Pancreatic Cancer: Ampullary cancer ESPAC-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. J Clin Oncol. 2011, 29 (Suppl): LBA4006
33.
go back to reference Kim R, Chabot J, Saif MW: Adjuvant treatment for ampullary cancer. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3–7, 2011. JOP. 2011, 12: 362-363.PubMed Kim R, Chabot J, Saif MW: Adjuvant treatment for ampullary cancer. Highlights from the “2011 ASCO Annual Meeting”. Chicago, IL, USA; June 3–7, 2011. JOP. 2011, 12: 362-363.PubMed
34.
go back to reference Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005, 54: 385-7. 10.1136/gut.2004.047191.CrossRefPubMedPubMedCentral Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005, 54: 385-7. 10.1136/gut.2004.047191.CrossRefPubMedPubMedCentral
Metadata
Title
Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin
Authors
Peter Bronsert
Ilona Kohler
Martin Werner
Frank Makowiec
Simon Kuesters
Jens Hoeppner
Ulrich Theodor Hopt
Tobias Keck
Dirk Bausch
Ulrich Friedrich Wellner
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-428

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine